UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

 
AMENDED FORM 12b-25
SEC FILE NUMBER
   
000-50112
 
AMENDED NOTIFICATION OF LATE FILING
CUSIP NUMBER
     

(Check one): [ X ] Form 20-F  [  ] Form 10-K [  ] Form 11-K [    ] Form 10-Q [  ] Form 10-D [  ] Form N-SAR [  ] Form N-CSR

For Period Ended:  December 31, 2017

[  ] Transition Report on Form 20-F
[  ] Transition Report on Form 20-F
[  ] Transition Report on Form 11-K
[  ] Transition Report on Form 10-Q
[  ] Transition Report on Form N-SAR
For the Transition Period Ended:  ____________________

Read Instruction (on back page) Before Preparing Form. Please Print or Type.
Nothing in this form shall be construed to imply that the Commission has verified any information contained herein.

If the notification relates to a portion of the filing checked above, identify the Item(s) to which the notification relates:
PART I — REGISTRANT INFORMATION

REPLICEL LIFE SCIENCES INC.
Full Name of Registrant
 
N/A
Former Name if Applicable
 
Suite 900 – 570 Granville Street
Address of Principal Executive Office (Street and Number)
 
Vancouver, British Columbia  Canada  V6C 3P1
City, State and Zip Code
PART II — RULES 12B-25(B) AND (C)

If the subject report could not be filed without unreasonable effort or expense and the registrant seeks relief pursuant to Rule 12b-25(b), the following should be completed. (Check box if appropriate)

 
(a)
The reason described in reasonable detail in Part III of this form could not be eliminated without unreasonable effort or expense
[X]
(b)
The subject annual report, semi-annual report, transition report on Form 20-F, Form 20-F, Form 11‑K, Form N-SAR or Form N-CSR, or portion thereof, will be filed on or before the fifteenth calendar day following the prescribed due date; or the subject quarterly report or transition report on Form 10-Q or subject distribution report on Form 10-D, or portion thereof, will be filed on or before the fifth calendar day following the prescribed due date; and
 
(c)
The accountant’s statement or other exhibit required by Rule 12b-25(c) has been attached if applicable.
 


PART III — NARRATIVE

State below in reasonable detail why Forms 10-K, 20-F, 11-K, 10-Q,10-D, N-SAR, N-CSR, or the transition report or portion thereof, could not be filed within the prescribed time period.  (Attach extra Sheets if Needed)
On May 1, 2018, the Registrant filed a Form NT.
The Form NT is amended by replacing the paragraph in Part III with the following:
The Registrant was unable to file, without unreasonable effort and expense, its Annual Report on Form 20-F for the period ended December 31, 2017 because the compilation and review of the information required to be in the annual report has not been finalized before the filing deadline.
PART IV — OTHER INFORMATION

(1)
Name and telephone number of person to contact in regard to this notification

 
Simon Ma
 
604.605.7011
 
 
(Name)
 
(Area Code) (Telephone Number)
 

(2)
Have all other periodic reports required under Section 13 or 15(d) of the Securities Exchange Act of 1934 or Section 30 of the Investment Company Act of 1940 during the preceding 12 months or for such shorter period that the registrant was required to file such report(s) been filed ? If answer is no, identify report(s).
Yes [ X ] No [  ]
     
(3)
Is it anticipated that any significant change in results of operations from the corresponding period for the last fiscal year will be reflected by the earnings statements to be included in the subject report or portion thereof ?
Yes [  ] No [ X ]
 
 
 
 
If so, attach an explanation of the anticipated change, both narratively and quantitatively, and, if appropriate, state the reasons why a reasonable estimate of the results cannot be made.
 
REPLICEL LIFE SCIENCES INC.
(Name of Registrant as Specified in Charter)

has caused this notification to be signed on its behalf by the undersigned hereunto duly authorized.

Date
May 7, 2018
 
By
/s/ Lee Buckler
 
 
 
 
Lee Buckler
 
 
 
 
Chief Executive Officer



 
RepliCel Life Sciences (PK) (USOTC:REPCF)
Historical Stock Chart
From Mar 2024 to Apr 2024 Click Here for more RepliCel Life Sciences (PK) Charts.
RepliCel Life Sciences (PK) (USOTC:REPCF)
Historical Stock Chart
From Apr 2023 to Apr 2024 Click Here for more RepliCel Life Sciences (PK) Charts.